Eloxx Pharmaceuticals, Inc. (ELOX): Operating Cash Flow
-$6.33M
Year ended 2025-12-31
-$16.02M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$6.33M | n/m | 2026-03-17, From 2025-01-01 |
| 2024-12-31 | -$4.71M | n/m | 2026-03-17, From 2024-01-01 |
| 2023-12-31 | -$14.34M | n/m | 2026-03-17, From 2023-01-01 |
| 2022-12-31 | -$31.84M | n/m | 2023-03-31, From 2022-01-01 |
| 2021-12-31 | -$35.00M | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | -$28.17M | n/m | 2022-03-30, From 2020-01-01 |
| 2019-12-31 | -$39.39M | n/m | 2022-03-30, From 2019-01-01 |
| 2018-12-31 | -$31.37M | n/m | 2021-03-12, From 2018-01-01 |
| 2017-12-31 | -$15.94M | n/m | 2020-03-06, From 2017-01-01 |
| 2016-12-31 | -$8.84M | n/m | 2019-03-14, From 2016-01-01 |
| 2015-12-31 | -$5.74M | n/a | 2018-03-16, From 2015-01-01 |
| No annual figure between 2014-06-30 and 2015-12-31. | |||
| 2014-06-30 | -$4.87M | n/m | 2014-09-29, From 2013-07-01 |
| 2013-06-30 | -$3.90M | n/m | 2014-09-29, From 2012-07-01 |
| 2012-06-30 | -$4.39M | n/m | 2014-09-29, From 2011-07-01 |
| 2011-06-30 | -$5.39M | n/m | 2013-09-11, From 2010-07-01 |
| 2010-06-30 | -$4.74M | n/a | 2012-10-26, From 2009-07-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | 2025-12-31 | -$6.33M | n/m |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $7.71M | n/m |
| Amgen Inc (AMGN) | 2025-12-31 | $9.96B | -13.3% |
| Repligen Corp (RGEN) | 2025-12-31 | $117.42M | -33.1% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | -$4.47M | n/m |
| Bio-Techne Corp (TECH) | 2026-06-30 | $292.07M | +1.6% |
| Biogen Inc. (BIIB) | 2025-12-31 | $2.20B | -23.3% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | -$18.92M | n/m |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $10.02B | -7.5% |
Compare ELOX, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗